Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756247 | 0.80 | RAB9A (0.81) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL27633440 | 0.79 | ALDH1A1 (0.52) | NPC1RAB9AKMT2AKDM4EHPGD | |
| SCHEMBL21239505 | 0.77 | FPR2 (0.45) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL4048384 | 0.77 | L3MBTL1 (0.63) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL9285165 | 0.75 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL17849580 | 0.74 | MEN1 (0.60) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL4131287 | 0.74 | — | — | |
| SCHEMBL29473470 | 0.73 | HPGD (0.47) | NPC1RAB9AKDM4EGAAHPGD | |
| SCHEMBL5852111 | 0.73 | RAB9A (0.70) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL1680647 | 0.73 | CA1 (0.46) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | NPC1 852/4885RAB9A 2652/4885MEN1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.